Mr James Frith

Mr James Frith

Labour — Bury North

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

I will make some progress. I am conscious that I need to give the right hon. Member for Tatton time to sum up. We should not assume that the regulator of today is incapable of learning from the regulator of the past. The test that I would apply is whether it listens when patients raise concerns and whether it shows a readiness to reform or renew. That matters for the future as much for the past. Science does not stand still while institutions catch up. New medicines and devices, and AI—which the good doctor, my hon. Friend the Member for Stroud (Dr Opher), referred to—are being introduced. My view is that innovation moves at the speed of trust. Good regulation should therefore be an enabler, not by lowering the bar, but by making the bar clear, rigorous and responsive to evidence. My hon. Friend is right that the Government accepted the 44 recommendations and will be responding formally with a plan for delivery. As he helpfully confirmed, the patient and public involvement and engagement plan is about giving patients much more information about the professional dialogue that happens around prescription. It also speaks to the wider point about the NHS app and about the digital verified information that we make available so that people can make informed decisions. Hon. Members raised concerns about the number of fatal covid vaccine reports that were investigated. The MHRA assesses every yellow card report involving a suspected adverse reaction with a fatal outcome. That includes all fatal covid vaccine reports. The MHRA should be judged on whether it can both learn honestly from where regulation has fallen short and give patients the confidence to benefit from where science takes us next. The hon. Member for Frome and East Somerset (Anna Sabine) talked about clinical trials, and she also raised Bedrocan. Through the British embassy in The Hague, I am in active discussions about the bankruptcy of the company and about suitable alternatives, but I am conscious that there can be significant consequences if people with epilepsy switch medication, and I am sensitive to that. A regulator succeeds ultimately because patients, their healthcare providers and the public have confidence in the quality and independence of its decisions. That is the standard that the Government expect from the MHRA, and we will continue to hold it to that standard. I again thank the right hon. Member for Tatton, my hon. Friend the Member for Blackley and Middleton South and all those who have contributed to this important debate.

More from Mr James Frith

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Mr James Frith's full parliamentary record including voting history, expenses and all other contributions, see the Mr James Frith report card.